U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H13N5O5S2
Molecular Weight 395.414
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFDINIR

SMILES

[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C3=CSC(N)=N3)C(O)=O

InChI

InChIKey=RTXOFQZKPXMALH-GHXIOONMSA-N
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1

HIDE SMILES / InChI
Molecular Formula C14H13N5O5S2
Molecular Weight 395.414
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/omnicef-drug.htm#I | https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/3255303

Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Cefdinir has minimal penetration across the blood-brain barrier and would not be considered therapeutic for CNS infections.

Originator

Approval Year

1997
172
Targets

Targets

Primary TargetPharmacologyConditionPotency
Myeloperoxidase
6
Target ID: P05164
Gene ID: 4353.0
Gene Symbol: MPO
Target Organism: Homo sapiens (Human)
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Curative
Approved
8429
CEFDINIR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.55 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.15 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.35 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.08 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.53 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.83 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.84 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.43 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.46 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.43 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
39%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7625793
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFDINIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
unhealthy
n = 5093
Health Status: unhealthy
Condition: Bacterial infections
Population Size: 5093
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea
Nausea
Rash (0.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
Disc. AE: Allergic reaction, Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Allergic reaction
Hypersensitivity reaction (serious)
Pseudomembranous colitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
AEs

AEs

AESignificanceDosePopulation
Rash 0.4%
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
unhealthy
n = 5093
Health Status: unhealthy
Condition: Bacterial infections
Population Size: 5093
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
Diarrhea Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
unhealthy
n = 5093
Health Status: unhealthy
Condition: Bacterial infections
Population Size: 5093
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
Nausea Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
unhealthy
n = 5093
Health Status: unhealthy
Condition: Bacterial infections
Population Size: 5093
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.13
Allergic reaction Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
Pseudomembranous colitis Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
Hypersensitivity reaction serious
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf
Page: p.9
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCTN2
66

PEPT1
20

PEPT2
10

OAT1
599

OAT3
642

CYP2B6
810

CYP
111
OAT3
339

CYP
270
CYP
76
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP
147
 no
CYP
147
 no
CYP2B6
1001
 no
PEPT1
22
 weak [Ki 11900 uM]
PEPT2
12
 weak [Ki 20100 uM]
OAT3
644
 yes [IC50 271.5 uM]
OAT1
603
 yes [IC50 692 uM]
OCTN2
71
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
270
 no
OAT3
339
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3485
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3485
ChemicalBook
CB7483101
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7483101
MolPort
MolPort-002-885-812
https://www.molport.com/shop/molecule-link/MolPort-002-885-812
Selleck Chemicals
Cefdinir(Omnicef)
http://www.selleckchem.com/products/Cefdinir(Omnicef).html
ZINC
ZINC000003927198
http://zinc15.docking.org/substances/ZINC000003927198
PubMed

PubMed

TitleDatePubMed
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure.
2001 Feb
A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study.
2005 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1.
2005 Oct 1
A favorable response to steroid therapy in a child with drug-associated acute vanishing bile duct syndrome and skin disorder.
2008 Apr
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

JP2003515526A
462
JP2004035543A
3
JP2004534053A
3
JP2007077123A
3
JP2008189688A
3
JP2008524265A
3
JP2008525531A
3
JP2008526782A
3
JP2009249380A
3
JP2010184925A
3
JP2011528275A
455
JP4792032B2
112

Sample Use Guides

In Vivo Use Guide
The total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Usual Adult Dose for Pneumonia: 300 mg orally every 12 hours for 10 to 14 days Acute exacerbations of chronic bronchitis: 300 mg orally every 12 hours for 5 to 10 days or 600 mg orally every 24 hours for 10 days Acute maxillary sinusitis: 300 mg orally every 12 hours or 600 mg orally every 24 hours for 10 days
Route of Administration: Oral
In Vitro Use Guide
Cefdinir had a much higher MIC90 against genotypic penicillin-resistant Streptococcus pneumoniae (gPRSP) than cefditoren and cefcapene (8 mg/L cefdinir vs. 1 mg/L cefditoren and cefcapene).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:54 GMT 2023
Edited
by admin
on Fri Dec 15 16:03:54 GMT 2023
Record UNII
CI0FAO63WC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFDINIR
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CEFDINIR [JAN]
Common Name English
FK-482
Code English
CEFDINIR [VANDF]
Common Name English
CEFDINIR [USP-RS]
Common Name English
CI-983
Code English
CEFDINIR [USAN]
Common Name English
cefdinir [INN]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL) (HYDROXYIMINO)ACETYL)AMINO)-3-ETHENYL-8-OXO-, (6R-(6.ALPHA.,7.BETA.(Z)))-
Common Name English
(6R,7R)-7-(((2Z)-(2-AMINO-4-THIAZOLYL)(HYDROXYIMINO)ACETYL)AMINO)-3-ETHENYL-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
CEFDINIR [USP MONOGRAPH]
Common Name English
CEFDINIR [MART.]
Common Name English
CEFDINIR [ORANGE BOOK]
Common Name English
CEFZON
Brand Name English
CEFDINIR ANHYDROUS
Common Name English
(-)-(6R,7R)-7-(2-(2-AMINO-4-THIAZOLYL)GLYOXYLAMIDO)-8-OXO-3-VINYL-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 72-(Z)-OXIME
Common Name English
Cefdinir [WHO-DD]
Common Name English
CEFDINIR [MI]
Common Name English
BMY-28488
Code English
OMNICEF
Brand Name English
SYN-7-(2-(2-AMINO-4-THIAZOLYL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID
Common Name English
FK 482
Code English
NSC-758926
Code English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
WHO-ATC J01DD15
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
LIVERTOX NBK548666
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
LIVERTOX 548358
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NCI_THESAURUS C357
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
WHO-VATC QJ01DD15
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000175488
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1097614
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
RXCUI
25037
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL927
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID8046084
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
NSC
758926
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
CHEBI
3485
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
MESH
C056814
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
SMS_ID
100000081816
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
MERCK INDEX
m3191
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY Merck Index
CAS
91832-40-5
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
DRUG CENTRAL
533
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
USAN
DD-77
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
INN
6408
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
WIKIPEDIA
Cefdinir
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
DAILYMED
CI0FAO63WC
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
PUBCHEM
6915944
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
LACTMED
Cefdinir
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
FDA UNII
CI0FAO63WC
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
NCI_THESAURUS
C28914
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
EVMPD
SUB07386MIG
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
DRUG BANK
DB00535
Created by admin on Fri Dec 15 16:03:54 GMT 2023 , Edited by admin on Fri Dec 15 16:03:54 GMT 2023
PRIMARY
Related Record Type Details
Structure of CEFDINIR MONOHYDRATE
SOLVATE->ANHYDROUS
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of CEFDINIR
BASIS OF STRENGTH->SUBSTANCE
Calculated on the anhydrous basis
ASSAY (HPLC)
USP
Structure of CEFDINIR MONOHYDRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of CEFDINIR LACTONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-(4-HYDROXYISOXAZOLE-3-CARBOXAMIDO)-8-OXO-3-VINYL-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, (6R,7R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CEFDINIR, (E)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-METHYL CEFDINIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of (2R)-2-((Z)-2-(2-AMINOTHIAZOL-4-YL)-2-(HYDROXYIMINO)ACETAMIDO)2-((2RS,5RS)-5-METHYL-7-OXO-2,4,5,7-TETRAHYDRO-1H-FURO(3,4-D)(1,3)THIAZIN-2-YL)ACETIC ACID
IMPURITY -> PARENT
The limit for the sum of the 4 isomers is 0.7%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of (6R,7R)-7-[2-(2-amino-4-thiazolyl)acetamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid
IMPURITY -> PARENT
Structure of THIAZOLYLACETYL GLYCINE OXIME HYDRATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of THIAZOLYLACETYL GLYCINE OXIME
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CEFDINIR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966